Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Plasmablastic Lymphoma × Bortezomib × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 66 Lymphoma 65 Lymphoma, Non-Hodgkin 43 Lymphoma, Follicular 42 Precursor Cell Lymphoblastic Leukemia-Lymphoma 41 Lymphoma, Large B-Cell, Diffuse 34 Waldenstrom Macroglobulinemia 33 Lymphoma, B-Cell, Marginal Zone 30 Leukemia, Lymphocytic, Chronic, B-Cell 28 Recurrence 18 Multiple Myeloma 17 Hodgkin Disease 17 Lymphoma, B-Cell 14 Leukemia, Myeloid, Acute 14 Burkitt Lymphoma 14 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13 Lymphoma, Large-Cell, Anaplastic 13 Leukemia 12 Immunoblastic Lymphadenopathy 12 Mycosis Fungoides 11 Lymphoma, T-Cell, Cutaneous 11 Lymphoma, Large-Cell, Immunoblastic 11 Sezary Syndrome 10 Lymphoma, T-Cell, Peripheral 10 Neoplasms, Plasma Cell 9 Neoplasms 9 Lymphoma, T-Cell 8 Myelodysplastic Syndromes 7 Lymphoma, Extranodal NK-T-Cell 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6

Interventions

Etoposide 6 Vincristine 5 Prednisone 5 Doxorubicin 5 Cyclophosphamide 5 Rituximab 4 prednylidene 3 deltacortene 3 daratumumab 2 Cytarabine 2 varlilumab 1 pomalidomide 1 merphos 1 ixazomib 1 carmustine, poliferprosan 20 drug combination 1 belantamab mafodotin 1 Vorinostat 1 Specimen Handling 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Methotrexate 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Hydrocortisone 1 Disulfides 1 Dexamethasone 1 Carmustine 1 CT-P10 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡